MedPath

Mitoxantrone

Generic Name
Mitoxantrone
Drug Type
Small Molecule
Chemical Formula
C22H28N4O6
CAS Number
65271-80-9
Unique Ingredient Identifier
BZ114NVM5P
Background

An anthracenedione-derived antineoplastic agent.

Indication

For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis

Associated Conditions
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Hodgkin's Lymphoma, Metastatic Breast Cancer, Non-Hodgkin's Lymphoma (NHL), Progressive Relapsing Multiple Sclerosis, Relapsed Leukemia, Relapsed Lymphomas, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Hormone refractory, advanced Prostate cancer, Relapsed Hepatocellular carcinoma
Associated Therapies
Autologous hematopoietic stem cell transplant
Clinical Trials
Related News

Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma

Phase 3
Conditions
Leukemia
Lymphoma
First Posted Date
2003-01-27
Last Posted Date
2011-01-21
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
1500
Registration Number
NCT00003728
Locations
🇵🇹

Hospital Escolar San Joao, Porto, Portugal

🇵🇹

Instituto Portugues de Oncologia Centro do Porto, SA, Porto, Portugal

🇫🇷

CHR de Besancon - Hopital Saint-Jacques, Besancon, France

and more 20 locations

Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma

Phase 3
Completed
Conditions
Lymphoma
First Posted Date
2003-01-27
Last Posted Date
2021-02-21
Lead Sponsor
UNICANCER
Target Recruit Count
179
Registration Number
NCT00003650
Locations
🇫🇷

Centre Leon Berard, Lyon, France

Combination Chemotherapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma

Phase 3
Completed
Conditions
Lymphoma
First Posted Date
2003-01-27
Last Posted Date
2013-06-26
Lead Sponsor
Lymphoma Trials Office
Target Recruit Count
310
Registration Number
NCT00005867
Locations
🇬🇧

Horton Hospital, Banbury, England, United Kingdom

🇬🇧

Hinchingbrooke Hospital, Huntingdon, England, United Kingdom

🇬🇧

Hull Royal Infirmary, Hull, England, United Kingdom

and more 43 locations

Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia

Phase 3
Completed
Conditions
Leukemia
Lymphoma
First Posted Date
2003-01-27
Last Posted Date
2013-06-12
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
392
Registration Number
NCT00002700
Locations
🇸🇰

Institute of Hematology & Transfusiology, University Hospital, Bratislava, Slovakia

🇧🇪

Hopital Universitaire Erasme, Brussels, Belgium

🇧🇪

Universitair Ziekenhuis Antwerpen, Edegem, Belgium

and more 41 locations

Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia

Phase 3
Conditions
Leukemia
Myelodysplastic Syndromes
First Posted Date
2003-01-27
Last Posted Date
2013-09-20
Lead Sponsor
Riverside Haematology Group
Target Recruit Count
400
Registration Number
NCT00003602
Locations
🇬🇧

Newcastle Upon Tyne Hospitals NHS Trust, Newcastle-Upon-Tyne, England, United Kingdom

Mitoxantrone With or Without Docetaxel in Treating Women With Metastatic Breast Cancer

Phase 3
Completed
Conditions
Breast Cancer
First Posted Date
2003-01-27
Last Posted Date
2013-08-02
Lead Sponsor
Arbeitsgemeinschaft fur Internistische Onkologie
Target Recruit Count
300
Registration Number
NCT00002544
Locations
🇩🇪

Diakonissen-Krankenhaus Stuttgart, Stuttgart, Germany

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma

Phase 3
Completed
Conditions
Lymphoma
First Posted Date
2003-01-27
Last Posted Date
2012-05-15
Lead Sponsor
Swiss Group for Clinical Cancer Research
Target Recruit Count
400
Registration Number
NCT00003215
Locations
🇨🇭

Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

🇨🇭

Inselspital, Bern, Bern, Switzerland

🇨🇭

Ratisches Kantons und Regionalspital, Chur, Switzerland

and more 9 locations

Combination Chemotherapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Phase 2
Conditions
Prostate Cancer
First Posted Date
2003-01-27
Last Posted Date
2011-03-01
Lead Sponsor
GERCOR - Multidisciplinary Oncology Cooperative Group
Registration Number
NCT00006114
Locations
🇫🇷

Hopital Saint-Louis, Amiens, France

🇫🇷

Polyclinique De Courlancy, Reims, France

🇫🇷

C.H. Senlis, Senlis, France

and more 7 locations

Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia

Phase 1
Completed
Conditions
Recurrent Adult Acute Lymphoblastic Leukemia
Recurrent Adult Acute Myeloid Leukemia
Secondary Acute Myeloid Leukemia
Untreated Adult Acute Lymphoblastic Leukemia
Untreated Adult Acute Myeloid Leukemia
Interventions
Other: pharmacological study
Other: laboratory procedure
First Posted Date
2003-01-27
Last Posted Date
2013-10-08
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
53
Registration Number
NCT00016016
Locations
🇺🇸

Johns Hopkins University, Baltimore, Maryland, United States

Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia

First Posted Date
2003-01-27
Last Posted Date
2012-08-27
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
472
Registration Number
NCT00052299
Locations
🇮🇹

Ospedale San Bortolo, Vicenza, Italy

🇳🇱

Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands

🇦🇹

A. oe. Krankenhaus der Barmherzigen Schwestern Kinderabteilung, Linz, Austria

and more 52 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy